US 12,403,125 B2
Use of Ovatodiolide against SARS-CoV-2
Zhen Yang, Shenzhen (CN); Yew-Min Tzeng, Taitung (TW); Linqi Zhang, Beijing (CN); Junmin Quan, Shenzhen (CN); Qing Chang, Lanzhou (CN); Qi Zhang, Beijing (CN); and Chien-Ming Lee, Taitung (TW)
Assigned to Peking University Shenzhen Graduate School, Shenzhen (CN); CNS Biotek Corp, Taichung (TW); and Gansu Evergreen Pharmaceuticals Co., Ltd., Lanzhou (CN)
Appl. No. 17/996,226
Filed by Peking University Shenzhen Graduate School, Shenzhen (CN); CNS Biotek Corp., Taichung (TW); and Gansu Evergreen Pharmaceuticals, Co., Ltd., Lanzhou (CN)
PCT Filed Apr. 17, 2020, PCT No. PCT/CN2020/085383
§ 371(c)(1), (2) Date Oct. 14, 2022,
PCT Pub. No. WO2021/208080, PCT Pub. Date Oct. 21, 2021.
Prior Publication US 2023/0143813 A1, May 11, 2023
Int. Cl. A61K 31/365 (2006.01); A61K 36/53 (2006.01); A61P 31/14 (2006.01)
CPC A61K 31/365 (2013.01) [A61K 36/53 (2013.01); A61P 31/14 (2018.01); A61K 2236/35 (2013.01); A61K 2236/39 (2013.01)] 8 Claims
 
1. A method for inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which comprises administering a safe and effective amount of Formula I compound—Ovatodiolide or a safe and effective amount of structural isomer of the Formula I compound—Ovatodiolide to a subject,

OG Complex Work Unit Chemistry